Long-Term Ibogaine Efficacy Study Initiated

Sandra Karpetas, Iboga Therapy House
Leah Martin, MAPS Ibogaine Study Coordinator

MONDAY, FEBRUARY 23 was not the beginning of just any old workweek, but an exciting and longawaited day. On that day we facilitated the introduction of the first participant into an observational case series of the long-term efficacy of ibogaine-assisted therapy and associated interventions in participants with opiate addiction treated at the Iboga Therapy House (ITH) in Vancouver, Canada.

This MAPS-sponsored study is intended to gather information to evaluate whether ibogaine-assisted therapy helps opioid-dependent people stop using opiates, use less, or practice moderated use after the therapy. For one year after therapy we will be collecting data from participants in the study, enabling us to examine whether ibogaine-assisted therapy facilitates positive changes or improvements in quality of life that result in decreased harms associated with chronic or mismanaged opiate use.

The road to getting this study approved and started was a long one. The protocol was originally designed as an outcome study, but it was later changed to an observational case study when the institutional review board expressed concerns that the initial design was too similar to a clinical trial. After three years, enduring numerous setbacks, the study is finally under way.

The conception of the study began in 2003, when MAPS Clinical Research Associate Valerie Mojeiko visited the ITH facility in Vancouver. At that time, the ITH was providing free ibogaine therapy to substance-dependent individuals as a response to the general lack of detoxification and treatment options. The five-day residential program provided an alternative to largely ineffective standard treatment models and provided a therapy based on the principles of harm reduction, health promotion, and psychedelic therapy. MAPS recognized the unique opportunity to study the outcomes of such a therapy as a potentially important contribution to the data available on the therapeutic uses of ibogaine. Thus, we began the process of developing a protocol for a study that would examine ibogaine-assisted therapy's potential in reducing harm and facilitating positive, healthy lifestyle changes.

The protocol design for the study is based on two primary and five secondary hypotheses. The primary hypotheses are that: 1) the ITH treatment program will result in changes in substance use, including decreases in average post-treatment scores on the Addiction Severity Index, with scores averaged over a one-year period; 2) the ITH treatment program will result in extended periods of abstinence post-treatment as quantified by average number of days post-treatment without use of opiates, and also by average time to first relapse.

The secondary hypotheses are that:

1. decreases in the Addiction Severity Index post-treatment will be correlated with high scores in both nadir and spiritual experiences as measured by the Peak Experience Profile;
2. the ITH treatment program will result in decreases in the Objective Opiate Withdrawal Scale and Subjective Opiate Withdrawal Scale immediately after treatment;
3. the ITH treatment program will result in extended periods of abstinence and/or extended periods of controlled drug use as quantified by amount of drugs used, and method and schedule of administration relevant to baseline;
4. average post-treatment scores of Addict Identity measured by the Social Identity Questionnaire-Substance Recovery (SIQ-SR) will be lower than pretreatment scores;
5. average posttreatment scores of Work, Recovery, Family and Religious Identity measured by the SIQ-SR will be higher than pretreatment scores.
Baseline data will be gathered prior to treatment at the ITH, with follow-up data gathered for one year following treatment. Most follow-up data will be gathered by telephone, since clients of the ITH program come from all over the United States and Canada. To verify participants' self reports, data from one or more of the participants' significant others will also be gathered by telephone.

Participants will be compensated $10 for each study visit or phone interview, up to a maximum of $160 for all 16 visits or interviews, to be paid at quarterly intervals throughout the course of the study and in payments valued at up to $40 per quarterly payment, equaling the form of a gift certificate to a grocery store or restaurant of their choice.

It's worth noting that Vancouver has a uniquely innovative approach to drug policy, outlined in the Four Pillars Drug Strategy. This strategy is focused on developing humane approaches to drug use through prevention, treatment, harm reduction, and law enforcement.

Ibogaine-assisted therapy fits within the pillars of both harm reduction and treatment. It has the potential to provide an alternative method of rapid detoxification from substance withdrawal, particularly for those resistant to standard 12-step-based treatment options or those seeking to detoxify more rapidly from substitution-based pharmacotherapies such as methadone. Aside from providing symptomatic relief from withdrawal symptoms, ibogaine-assisted therapy can also provide psychotherapeutic benefits when used with proper intention in a safe and supportive environment.

In 2003 and 2004, the ITH collected preliminary anecdotal data from 20 people who received therapy at the facility. Though the outcome data was promising, the ITH was forced to end this preliminary research and the offering of free therapies in fall 2004 following the loss of program funding when Canadian philanthropist Marc Emery was extradited to the United States for the sale of cannabis seeds.

In early 2005, the ITH sought funding by writing a grant proposal to a new Canadian federal fund, the Drug Strategy Community Initiatives Fund (DSCIF), in hopes of reopening the facility and continuing the research. Although the submission was intriguing to the grant review board, the scope of the project was considered to be more than what the DSCIF could support at that time. In the meantime, the protocol development for the MAPS study continued, and the ITH began working to reopen the ITH as a nonprofit business.

These were challenging times, yet MAPS considered the study's potential too great to give up. In early 2006, MAPS submitted the first version of the study protocol to the institutional review board of IRB Services in Canada. Finally, on Aug. 11, 2006, the protocol received unconditional approval from the IRB. The ITH reopened its doors in March 2006 to continue offering ibogaine-assisted therapy in a beautiful new setting near the ocean and forest. It has made numerous improvements to its program and hired a new staff that includes a nurse, emergency medical technicians, a physician, facilitators, an art therapist, a substance counselor, and bodyworkers skilled in various healing modalities.

After more than three-and-a-half years of preparation, patience, and diligence, we are excitedly under way with the implementation of this groundbreaking study! Stay tuned for updates.

For more information about the study, see the protocol on the MAPS Web site: maps.org/ibogaine. For more information about the Iboga Therapy House visit: ibogatherapyhouse.net.

< Return to Table of Contents: spring/summer 2007 Issue - "The Chrysalis Stage"
Summer 2008  Vol. 18, No. 2  Phoenix Rising: A Review of MAPS Research
Spring 2008  Vol. 18, No. 1  Special Edition: Technology and Psychedelics
Winter 2007  Vol. 17, No. 3  MAPS 06-07 Fiscal Yearly Report
Autumn 2007  Vol. 17, No. 2  Special Edition: Psychedelics and Self-Discovery
Spring/Summer 2007  Vol. 17, No. 1  The Chrysalis Stage
Winter 2006-7  Vol. 16, No. 3  Low Maintenance/High Performance
Autumn 2006  Vol. 16, No. 2  Technologies of Healing
Spring 2006  Vol. 16, No. 1  MAPS' 20th Anniversary
Winter 2005  Vol. 15, No. 3  MAPS final year as a teenager
Summer 2005  Vol. 15, No. 2  Israel Conference: MDMA/PTSD Research
Spring 2005  Vol. 15, No. 1  Accelerating flow of work and time
Autumn 2004  Vol. 14, No. 2  Rites of Passage: Kids and Psychedelics
Summer 2004  Vol. 14, No. 1  10 stamps and $250,000
Winter 2003  Vol. 13, No. 2  Holy Fire
Spring 2003  Vol. 13, No. 1  60th Anniversary of the Discovery of LSD
Autumn 2002  Vol. 12, No. 3  Vision
Summer 2002  Vol. 12, No. 2  "From celebration to frustration, and back again."
Spring 2002  Vol. 12, No. 1  Sex, Spirit & Psychedelics 2002
Autumn 2001  Vol. 11, No. 2  "In the future, it will be called Despair."
Spring 2001  Vol. 11, No. 1  "A Tidal Wave of Ecstasy!"
Autumn 2000  Vol. 10, No. 3  Creativity 2000
Summer 2000  Vol. 10, No. 2  Endings and Beginnings
Spring 2000  Vol. 10, No. 1  Making History in Slow Motion
Winter 1999/00  Vol. 9, No. 4  To the Ends of the Earth for MDMA Research...
Autumn 1999  Vol. 9, No. 3  MAPS' long-standing efforts to conduct...
Summer 1999  Vol. 9, No. 2  MAPS has come full circle...
Spring 1999  Vol. 9, No. 1  Patience, persistence and passion
Winter 1998/99  Vol. 8, No. 4  One of special pleasures of directing MAPS...
Autumn 1998  Vol. 8, No. 3  The Ayahuasca Issue (with Hofmann interview)
Summer 1998  Vol. 8, No. 2  Emotionally Powerful Anecdotes...
Spring 1998  Vol. 8, No. 1  Death Has a Way of Focusing One's Attention
Autumn 1997  Vol. 7, No. 4  Celebration is in Order
Summer 1997  Vol. 7, No. 3  Time Horizons
Spring 1997  Vol. 7, No. 2  Synchronicity
Winter 1996/97  Vol. 7, No. 1  Learning to Crawl
Autumn 1996  Vol. 6, No. 4  An Invitation for Dialogue
Summer 1996  Vol. 6, No. 3  Budding Research
New Year 1996  Vol. 6, No. 2  Sending Down Roots
Autumn 1995  Vol. 6, No. 1  Baby Steps
Summer 1995  Vol. 5, No. 4  Opportunity Amidst Obstacles
Winter 1994/95  Vol. 5, No. 3  Clinical Trials and Tribulations
<table>
<thead>
<tr>
<th>Issue</th>
<th>Volume/Publication</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autumn 1994</td>
<td>Vol. 5, No. 2</td>
<td>Building Towards Clinical Trials</td>
</tr>
<tr>
<td>Spring 1994</td>
<td>Vol. 4, No. 4</td>
<td>Laying the Groundwork</td>
</tr>
<tr>
<td>Winter 1993/94</td>
<td>Vol. 4, No. 3</td>
<td>A Time of Tests</td>
</tr>
<tr>
<td>Summer 1993</td>
<td>Vol. 4, No. 2</td>
<td>So Close Yet So Far</td>
</tr>
<tr>
<td>Spring 1993</td>
<td>Vol. 4, No. 1</td>
<td>Remembrance and Renewal</td>
</tr>
<tr>
<td>Winter 1992/93</td>
<td>Vol. 3, No. 4</td>
<td>Forging New Alliances</td>
</tr>
<tr>
<td>Summer 1992</td>
<td>Vol. 3, No. 3</td>
<td>Building on Common Ground</td>
</tr>
<tr>
<td>Spring 1992</td>
<td>Vol. 3, No. 2</td>
<td>Small Steps, Gradual Progress, New Opportunities</td>
</tr>
<tr>
<td>Winter 1991/92</td>
<td>Vol. 3, No. 1</td>
<td>The Rekindling of a Thousand Points of Light</td>
</tr>
<tr>
<td>Summer 1991</td>
<td>Vol. 2, No. 2</td>
<td>MDMA protocol development with cancer patients</td>
</tr>
<tr>
<td>Winter 1990/91</td>
<td>Vol. 2, No. 1</td>
<td>MAPS' Swiss pharmacologically-assisted psychotherapy conference</td>
</tr>
<tr>
<td>Autumn 1990</td>
<td>Vol. 1, No. 3</td>
<td>What and Who is MAPS?</td>
</tr>
<tr>
<td>Summer 1989</td>
<td>Vol. 1, No. 2</td>
<td>Switzerland Leads the Way</td>
</tr>
<tr>
<td>Summer 1988</td>
<td>Vol. 1, No. 1</td>
<td>MDMA can become a legal medicine</td>
</tr>
</tbody>
</table>